Boehringer’s Giotrif gets wider lung cancer use in Europe
Boehringer Ingelheim’s Giotrif (afatinib) oral lung cancer drug has a widened use in Europe after it was approved for patients with squamous cell carcinoma of the lung.
Approval means Giotrif is approved in the second largest sub-type of non-small cell lung cancer (NSCLC) representing around 20-30% of cases.
The full indication is for treatment of patients with advanced squamous cell carcinoma of the lung, whose disease has progressed on or after treatment with platinum-based chemotherapy.
Approval was based on results of the LUX-Lung 8 study, which chowed significantly improved overall survival compared with Roche’s rival Tarceva (erlotinib).
Results showed Giotrif reduced risk of progression by 19% and reduced the risk of death by 19% compared with Tarceva, with similar rates of similar adverse events.
Some side effects were more common with Giotrif, however, such as severe diarrhoea, which occurred in 10% of Giotrif patients compared with 2% of Tarceva patients.
Giotrif, which according to a GlobalData forecast could generate annual sales of $688 million in 2022, is already approved in more than 60 countries for EGFR mutation positive NSCLC.
Hikma wants new generics business Roxane to boost sales
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.